Multiple Myeloma
Conditions
Interventions
lenalidomide
Sponsors
Kansai Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Without severe complications • At least one prior therapy of multiple myeloma • Agree to register and follow RevMate • In the patients receiving the notice, fully briefed for the consent document and other documents given explanation about the contents of the study physician or study investigator, agreed in writing to voluntarily participate in the study by have been obtained
Exclusion criteria
Exclusion criteria: • Cardiac infarction within 6 months • Deep vein thrombosis or pulmonary embolism within 3 years • Tuberculosis, herpes simplex keratitis, mycosis, or other active infections at baseline • Uncontrollable diabetes mellitus, hypertension, peptic ulcer, or glaucoma • Posterior capsule opacification • Patients with mental illness • Those who are considered as inappropriate to register by attending physicians • Pregnant or breast feeding females • Known hypersensitivity to dexamethasone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Association of plasma cytokine changes with response rate, PFS, OS and safety of lenalidomide therapy Association between factors for thromboembolism and adverse events of lenalidomide therapy | — |
Countries
Japan
Contacts
Public ContactShosaku Nomura
Kansai Medical University The First Department of Internal Medicine
Outcome results
None listed